Vimarsana
Biggest News Aggregation in the World

Page 5 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Erdafitinib Elicits Responses in FGFR-altered Solid Tumors - Vimarsana News

Erdafitinib Elicits Responses in FGFR-altered Solid Tumors

Treatment with erdafitinib resulted in clinical benefit for patients with advanced solid tumors harboring susceptible FGFR alterations who had exhausted all other treatment options, meeting the primary end point of overall response rate of the phase 2 RAGNAR trial.

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights - Vimarsana News

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530 - Vimarsana News

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia - Vimarsana News

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large...

ADC demonstrates meaningful survival data for HER2 cancers - Vimarsana News

ADC demonstrates meaningful survival data for HER2 cancers

ENHERTU® has demonstrated clinically meaningful progression-free survival and overall survival in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. The...